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Introduction: Ibuprofen is one of the nonsteroidal anti-inflammatory drugs that have been shown to selectively
lower pathogenic amyloid beta-peptide (Aβ)42 without impairing overall γ-secretase activity in vitro. This γ-secretase
modulator (GSM) activity has been hypothesized to contribute to the reduction in risk of developing Alzheimer’s
disease in chronic users of nonsteroidal anti-inflammatory drugs. However, it is unclear whether ibuprofen, within
therapeutic dosing range, demonstrates GSM activity in humans. In this study, we evaluated the effects of ibuprofen
and a second-generation GSM, GSM-1, on Aβ levels in cerebrospinal fluid and plasma of young nonhuman primates
and humans.
Methods: Five to seven conscious cynomolgus monkeys (Macaca fascicularis) were nontreated or treated with
30 mg/kg GSM-1 or 50 or 100 mg/kg ibuprofen and the plasma and cerebrospinal fluid were sampled at −8, 0
(baseline or right before treatment), 2, 4, 6, 8, 12, and 24 h postdosing. In addition, sixteen healthy human
subjects were randomly assigned to receive either placebo or 800 mg ibuprofen given by intravenous administration
and plasma were collected at 0 (before drug infusion), 0.5, 1, 2, 4, 6, 8, 10, and 24 h after dosing.
Results: A single dose of GSM-1 (30 mg/kg) decreased the ratio of Aβ42 to Aβ40 to 60 % in plasma and the ratio
of Aβ42 to total Aβ to 65 % in cerebrospinal fluid from baseline to postdosing in monkeys. However, no significant
changes were detected following ibuprofen treatment at 100 mg/kg. Consistent with the results from nonhuman
primates, ibuprofen did not alter plasma Aβ levels in human volunteers after a single 800 mg dose.
Conclusions: GSM-1 exerted potent lowering of the ratio of Aβ42 to Aβ40 in nonhuman primates but the
hypothesized GSM activity of ibuprofen could not be demonstrated in nonhuman primates and humans after
acute dosing.Introduction
Alzheimer’s disease (AD) is the most common age-
associated neurodegenerative disease and is accompanied
by hippocampal and brain atrophy and is manifested
clinically with memory and cognitive impairments [1].
Pathologically, AD is characterized by deposition of
extracellular amyloid beta-peptide (Aβ) in senile plaques,
intracellular neurofibrillary tangles, and loss of synapses
and neurons [2]. The cause of AD is still unclear. Much
research focuses on the amyloid cascade hypothesis, which
states that aggregated forms of Aβ initiate a cascade of* Correspondence: edkoo@ucsd.edu
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AD [3, 4]. Aβ is derived by sequential proteolysis of the
amyloid precursor protein (APP) by β- and γ-secretases to
generate peptides of 36–42 amino acids in length [5, 6].
The longer but minor species, Aβ42, is widely believed to
represent a more pathogenic species as it aggregates faster
than the shorter Aβ40 species and demonstrates toxicity
in vitro and in vivo [7, 8]. Mutations in PSEN1, PSEN2
and APP genes, causing early onset familial AD (FAD)
have been shown to alter Aβ production, with the majority
of PSEN mutations elevating the ratio of Aβ42/Aβ40
[9–11]. At present there is no effective treatment for
AD and current medications are mildly effective in treat-
ing the symptoms but do not show disease-modifying
effects [12].
Because γ-secretase cleavage is the final step in Aβ pro-
duction, inhibition or modulation of γ-secretase serves ale distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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nondiscriminant inhibition of γ-secretase inhibitors (GSI),
γ-secretase modulators (GSMs) are thought to be intrin-
sically safer as they target the pathogenic Aβ42 species
without inhibiting normal APP processing or cleavage of
other γ-secretase substrates, such as Notch and ErbB4
[13, 14]. GSMs increase the processivity of γ-secretase to
promote further cleavage of Aβ42 peptides, resulting in
decreased Aβ42 and increased shorter species, such as
Aβ37 and Aβ38, thereby reducing the ratio of Aβ42/Aβ40
[15]. GSM activity was first observed in a subset of non-
steroidal anti-inflammatory drugs (NSAIDs), such as ibu-
profen, indomethacin and sulindac sulfide, when used at
high doses, an observation that might explain the epi-
demiological link between NSAID use and AD risk reduc-
tion [16–18]. Since the initial description of the GSM
activity of certain NSAIDs, numerous GSMs with more
potent activity have been reported [19–21]. However, it
is unclear whether NSAIDs exhibit GSM activity in humans
as this has never been tested. Thus, if such compounds
were to be used prophylactically as potential preventive
treatment, it is important to establish whether the NSAIDs
with GSM activity in vitro behave similarly in vivo.
Although GSMs have shown efficacy in preclinical
models, tarenflurbil, the R-enantiomer of flurbiprofen was
shown not to be effective in a late-phase human clinical
trial possibly due to lack of potency or brain penetration
[22, 23]. Because newer GSMs have not yet demonstrated
clinical efficacy, we chose to examine whether ibuprofen
has GSM activity in nonhuman primates and humans
following acute dosing. Ibuprofen is one of the NSAIDs
with GSM activity in preclinical studies and chronic use
has been linked to a reduction in AD risk [16, 18, 24–27].
However, it is unclear whether the drug, within the thera-
peutic dosing range, can modulate Aβ42 levels in vivo in
humans. Consequently, in this study, we evaluated the ef-
fects of ibuprofen and a potent second-generation GSM,
GSM-1 [28], on plasma and cerebrospinal fluid (CSF)
Aβ levels in young cynomolgus monkeys, a model that
has been used to examine GSI efficacy in vivo [29]. In
addition, we took advantage of the recent US Food and
Drug Administration (FDA) approval of an intravenous
(IV) formulation of ibuprofen (Caldolor) to examine the
effect of a single high dose of ibuprofen on plasma Aβ
levels in humans. In contrast to GSM-1, we failed to de-
tect any GSM activity of ibuprofen on plasma and CSF




All compounds and reagents were from commercial venders
as follows: IV-ibuprofen (Caldolor; Cumberland Pharmaceu-
ticals, Nashville, TN, USA); ibuprofen (Nurofen; IbuprofenB.P. 200 mg; Reckitt Benckiser, Slough, UK); Aβ38 and
Aβ40 enzyme-linked immunosorbent assay (ELISA) kits
(IBL-International, Toronto, Canada); INNOTESTAβ42 kit
(Innogenetics, Alpharetta, GA, USA); MSD Aβ Triplex kit
(Meso Scale Discovery, Gaithersburg, MD, USA); and Ibu-
profen ELISA kit (Neogen, Lexington, KY, USA). GSM-1
was custom synthesized at Mayo Clinic (Jacksonville, FL,
USA) by following published procedures [30] and verified
by a combination of thin-layer chromatography (TLC),
nuclear magnetic resonance (NMR) and electrospray
ionization (ESI) analyses. The in vitro efficacy has been
confirmed in previous publications [31, 32]. Antibodies
included Ab9 (Mayo Clinic), 82E1 (IBL-International),
4G8-biotin (Covance, Princeton, NJ, USA), streptavidin-
HRP (Jackson ImmunoResearch, West Grove, PA, USA),
Aβ42 specific antibodies MM26-2.1.3 (Mayo Clinic), and
6E10-HRP (Covance).
Cell culture
Chinese hamster ovary (CHO) cells stably expressing wild-
type APP751 (APP-WT) and CHO cells stably expressing
APP751 with the Val717Phe familial AD mutation (APP-
V717F) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum, 50 U/ml penicillin and 50 μg/ml streptomycin
at 37 °C in a humidified 5 % CO2/95 % air atmosphere.
Drug treatments in cynomolgus monkeys
All procedures related to the use of animals were approved
by the Institutional Animal Care and Use Committee
(IACUC) of Maccine Pte Ltd (Singapore). A total of seven,
non-naive female cynomolgus macaques (Macaca fascicu-
laris), aged 2.5–5 years, were studied. A cisterna magna
catheter and port system was surgically implanted in each
monkey [33] and animals were allowed recover for 2–3
weeks prior to treatment. Following recovery, the animals
were studied sequentially over the subsequent weeks
under different conditions, which were changed on a
weekly basis. In the first week, no treatment was given
and the CSF and plasma were sampled from the mon-
keys at −8, 0 (baseline), 2, 4, 6, 8, 12, and 24 h. In the
following weeks, the animals were treated with GSM-1
(30 mg/kg), IV-ibuprofen (50 mg/kg), or ibuprofen (100
mg/kg) with a 7-day rest/washout period between each
treatment condition.
IV-ibuprofen was diluted with saline to 4 mg/ml and IV
infused to achieve the dose of 50 mg/kg. Ibuprofen was
supplied as a 200 mg caplet. Each animal was provided
with one caplet of 200 mg ibuprofen and one capsule con-
taining the weighed amount of the grounded ibuprofen
caplet to meet the required dose of 100 mg/kg. Ibuprofen
was administered by using an appropriate catheter tube.
GSM-1 was prepared by dissolving in 5 % (v/v) ethanol,
10 % (v/v) solutol HS-15 and 85 % (v/v) Milli-Q water on
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achieved by gavage.Human study
The study was approved by Human Research Protections
Program and the Institutional Review Board at the Univer-
sity of California, San Diego, and carried out at the Shiley-
Marcos Alzheimer’s Disease Research Center and Clinical
Translational Research Institute at the University of
California, San Diego. Subjects were recruited and screened.
Exclusion criteria included contraindication to blood draw,
chronic major psychiatric disorders, history of peptic ulcer
or upper gastrointestinal bleed, significant medical illness,
hypersensitivity/allergy to ibuprofen or other NSAID drugs,
and regular use of aspirin or NSAIDs. All subjects provided
written informed consent to participate in this study.
Sixteen eligible healthy subjects, 6 men and 10 women
from 21 to 35 years of age, participated in this study.
After an overnight fast, the subjects were randomized to
receive 800 mg IV-ibuprofen or placebo. Plasma was
sampled at time 0 (before drug infusion), 0.5, 1, 2, 4, 6,
8, 10, and 24 h after dosing.Sandwich ELISA
Quantification of total Aβ and Aβ42 peptides was carried
out with sensitive ELISAs. For total Aβ, Ab9 antibody
(20 μg/ml), which recognizes Aβ1–16, was used as capture
and 4G8-biotin (20 μg/ml) and strepavidin-HRP were
used as reporter. Aβ42 was measured by the Aβ42 end-
specific MM26-2.1.3 antibody (50 μg/ml) [34] as capture
antibody and 6E10-HRP (1 μg/ml) as reporter. 4G8 and
6E10 recognize Aβ17–24 and Aβ1–16, respectively. CSF
Aβ38 was measured by a commercial Aβ38 ELISA kit
(IBL), following manufacturer’s instructions. Plasma Aβ
species were measured by either Aβ40 (IBL), Aβ42
(Innotest) or Aβ Triplex (MSD) kit, following manufac-
turer’s instructions. Plasma levels of ibuprofen were
measured by a commercial ELISA system (Neogen), fol-
lowing manufacturer’s instructions.Fig. 1 The efficacy of ibuprofen and GSM-1 on selectively decreasing Aβ42 in
media from cells stably expressing wild-type APP751 (APP-WT) and cells stably
after drug incubation for 24 h were evaluated by enzyme-linked immuno
were repeated at least twice. Results are presented as mean ± range. GSMStatistical analysis
The effects of drugs on CSF and plasma Aβ ratios in
monkeys and plasma Aβ ratios in humans were analyzed
by a two-way analysis of variance with a post hoc Bon-
ferroni posttest (GraphPad Prism, La Jolla, CA, USA).
Results
GSM activity of ibuprofen and GSM-1 in vitro
This study was designed to test the physiological activity
of two GSMs in primates following acute dosing: a NSAID
ibuprofen and GSM-1, an experimental compound. Before
evaluating the effects in vivo, we first confirmed their
GSM activity in vitro. CHO cells stably expressing
APP-WT or APP-V717F were incubated with ibuprofen
or GSM-1 for 24 h. Conditioned media were collected and
Aβ42 and total Aβ levels were quantified by ELISA ana-
lyses. Both ibuprofen and GSM-1 significantly reduced the
ratio of Aβ42 to total Aβ in a dose-dependent manner, in-
dicating the modulation of γ-secretase activity (p < 0.001;
Fig. 1). As expected, GSM-1 showed greater potency with
50 % reduction at 0.2 μM whereas ibuprofen required
250–500 μM to reach similar level of Aβ42 changes
(Fig. 1).
Effects of ibuprofen and GSM-1 on Aβ in cynomolgus
monkeys
Seven young cynomolgus monkeys were first studied
without drug treatment to determine the basal Aβ levels
over a 32-hour period. The CSF and plasma samples were
collected at −8, 0 (baseline), 2, 4, 6, 8, 12 and 24 h after
baseline. Aβ42, Aβ38 and total Aβ levels in CSF samples
were measured. During the observation period, there was
variation in Aβ levels in untreated animals (Fig. 2a–c)
without a clear diurnal pattern, consistent with the reports
from catheter studies in humans [35]. Animals were
then treated with drugs in subsequent weeks sequen-
tially. Between each treatment, all animals were rested
for 1 week to allow drug washout. In drug-treated animals,
GSM-1 significantly reduced Aβ42 and increased Aβ38
levels (both p < 0.001), but did not change total Aβ levelsvitro. Total amyloid beta-peptide (Aβ) and Aβ42 levels in conditioned
expressing APP751 with the Val717Phe familial AD mutation (APP-V717F)
sorbent assays (ELISAs) and ratios were compared. All experiments
gamma-secretase modulator
Fig. 2 The effects of ibuprofen and GSM-1 on CSF and plasma Aβ levels in cynomolgus monkeys. Cerebrospinal fluid (CSF) and plasma samples
were collected at indicated time points and amyloid beta-peptide (Aβ) levels were measured. Levels of total Aβ (a), Aβ42 (b) and Aβ38 (c) were
compared in CSF samples. Ratios of Aβ42 to total Aβ (d) and Aβ38 to total Aβ (e) were compared in CSF samples and ratios of Aβ42/Aβ40 were
compared in plasma samples (f). The levels and ratios were normalized to baseline (time 0 or before drug dosing) and shown as percentages of
baseline. Seven monkeys were used in the no-treatment group. However, the catheters in two animals did not maintain patency during the study
period. Therefore, fewer animals received the single dose of GSM-1 (n = 6) or ibuprofen (n = 5). Results are presented as mean ± SEM; *p < 0.05,
**p < 0.001. GSM gamma-secretase modulator
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(from 267.1 ± 60.0 (mean ± SD) to 183.5 ± 96.1 pg/mL)
was noted at 12 h postdosing (Fig. 2b). Meanwhile, Aβ38
levels increased ~90 % maximally (from 1033.3 ± 300.0 to
1954.8 ± 698.6 pg/mL; Fig. 2c) at 8 h postdosing. GSM-1
decreased the ratio of Aβ42 to total Aβ up to 35 % at 12 h
after administration (p < 0.001; Fig. 2d) and increased
the ratio of Aβ38 to total Aβ maximally by 70 % after 8 h
(p < 0.05; Fig. 2e). In light of the CSF results, the effects of
GSM-1 were mirrored in plasma. Specifically, the ratio of
Aβ42/Aβ40 in plasma was markedly decreased (p < 0.001;
Fig. 2f). This was evident as early as 2 h following drug ad-
ministration and plateaued starting at 4 h. GSM-1 reduced
the ratio of Aβ42/Aβ40 up to 40 % at 6 h after dosing.These changes in plasma Aβ were more rapid than were
observed in CSF, where the maximum reduction was
delayed to 8–12 h, but the magnitude of reduction was
similar (Fig. 2d,f ).
In contrast to GSM-1, no changes could be detected
in any of the Aβ levels or ratios in either CSF or plasma
following ibuprofen administration at either 50 mg/kg
(data not shown) or 100 mg/kg (Fig. 2). Specifically, there
was no reduction in the ratio of Aβ42 to total Aβ nor an
increase in the ratio of Aβ38 to total Aβ in CSF and no
change in the ratio of Aβ42/Aβ40 in plasma after ibupro-
fen treatment (Fig. 2d–f ). In sum, these results showed
that a single-dose administration of GSM-1 potently mod-
ulated Aβ production. In contrast, a single high dose of
Table 1 Demographic data and subject characteristics at
baseline (n = 7 for each group)
Placebo Ibuprofen
Age (mean ± SD) 27.4 ± 5.5 25.7 ± 3.6
Sex 3 females, 4 males 5 females, 2 males
Aβ38 Level (pg/mL) 199.1 ± 276.0 344.6 ± 603.5
(mean ± SD (lowest; highest)) (25.7; 746.8) (25.6; 1694.4)
Aβ40 Level (pg/mL) 348.2 ± 152.8 468.0 ± 409.5
(mean ± SD (lowest; highest)) (229.2; 659.1) (259.9; 1392.2)
Aβ42 Level (pg/mL) 183.8 ± 257.6 295.5 ± 547.3
(mean ± SD (lowest; highest)) (23.2; 681.4) (27.5; 1524.5)
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production in monkeys that would be consistent with
γ-secretase modulation.
Effects of ibuprofen on Aβ in humans
We next evaluated the effects of IV-ibuprofen or placebo
on plasma Aβ levels in humans. Nineteen subjects were
screened and sixteen eligible healthy subjects were en-
rolled in the study (Fig. 3). With eight subjects in each
group, we anticipated being able to detect changes of
20 % or more in plasma Aβ42 levels if ibuprofen showed
GSM activity based on a GSI study [36]. Subjects were
randomly assigned to receive either placebo or 800 mg
IV-ibuprofen. The latter dose reflects the highest FDA-
approved single human dose given four times daily (total
of 3.2 g per day). Given the plasma results of GSM-1
treatment in monkeys, blood samples were drawn at
baseline (before drug infusion), 0.5, 1, 2, 4, 6, 8, 10, and
24 h after dosing. During the study period, no adverse
events were observed in subjects. The levels of Aβ38,
Aβ40 and Aβ42 in plasma samples were measured. Sub-
ject demographics and baseline Aβ levels are summarized
in Table 1. Baseline plasma levels of Aβ peptides showed
substantial variability between subjects. The Aβ42 levels
ranged from 23.2 to 1524.5 pg/mL, and the Aβ40 levels
ranged from 229.2 to 1392.2 pg/ml. When the baseline ra-
tios of Aβ42/Aβ40 were compared, most subjects reflected
the generally minor contribution of Aβ42 to Aβ40 with
ratios of approximately 0.1, but several subjects (#11,
14 and 15) showed relatively higher Aβ42 levels with
ratios of approximately 1 (Fig. 4a). In contrast, the ra-
tios of Aβ42/Aβ38 ranged from 0.5 to 1 with the major-
ity around 1 (Fig. 4b). Comparing either the ratios of
Aβ42/Aβ40 and Aβ38/Aβ40 in plasma in subjects who
received ibuprofen versus placebo, no changes could be
detected after drug treatment (Fig. 4c,d). These resultsFig. 3 Participation flow chart for the human study. Nineteen subjects
were recruited and screened. Three subjects were excluded from the
study: two due to high blood creatinine level and invisible veins,
respectively, and one declined to participate after screening. Samples
from two subjects were excluded for analysis due to technical reasons.
IV intravenousdemonstrated that a single dose of 800 mg ibuprofen
did not result in any acute changes in Aβ production in
humans, a finding consistent with the observations from
nonhuman primates.
The negative results in plasma after ibuprofen treatment
in both humans and monkeys were unexpected. Although
IV administration should have resulted in near complete
systemic drug delivery, it is important to confirm adequate
drug levels in plasma in humans. Because the half-life of
ibuprofen is approximately 2 h in plasma [37], drug levels
were measured in samples at 0, 1, 2, 4, and 8 h after infu-
sion. For comparison, we also analyzed the monkey CSF
and plasma samples at 0, 2, 4, and 8 hours after oral
dosing with 100 mg/kg ibuprofen. In humans, the high-
est plasma levels of ibuprofen were seen at 1 hour, the
first time sampled, and returned to baseline levels by 8 h
(Fig. 5a). The maximum average concentration of total
ibuprofen (bound and unbound) (Cmax total) was 441.63 ±
113.84 (mean ± SD) μM (Table 2). Because ibuprofen has
been reported to be ~99 % bound to plasma proteins [38],
free unbound concentration of ibuprofen was estimated to
be approximately 4.4 μM. In monkeys, ibuprofen concen-
trations were highest at 2 h, again the first sampled time
point, after oral administration in all but one animal in
both plasma and CSF (Fig. 5b,c). The Cmax total in CSF was
12.24 μM, which is ~ 1 % of the Cmax total in plasma
(1060.33 μM) (Table 2). Comparing the area under curve
from 0 to 8 h, the calculated CSF:plasma ratio was about
0.01 in monkeys after a single dose of 100 mg/kg ibupro-
fen (Table 2), consistent with the generally low brain pene-
tration of NSAIDs [39, 40]. Finally, interleukin (IL)-1β and
IL-6 levels were assayed from human plasma and, not sur-
prisingly, there were no differences between control and
ibuprofen-treated groups (data not shown) because there
is no documented suppression of these inflammatory
markers by ibuprofen in healthy individuals [41].
Discussion
In this study, we sought to test whether ibuprofen
demonstrates any GSM activity in plasma and CSF in
Fig. 4 The effect of a single dose of 800 mg IV-ibuprofen on Aβ levels in humans. Plasma samples were collected at indicated time points and
amyloid beta-peptide (Aβ) levels were analyzed. Ratios of Aβ42/Aβ40 (a) and Aβ42/Aβ38 (b) at baseline (before infusion) were compared
among subjects. Then ratios of Aβ42/Aβ40 (c) and Aβ38/Aβ40 (d) between placebo and ibuprofen groups were compared. Results are
presented as mean ± SEM
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ing. Contrary to previous in vitro studies, a single
high dose of ibuprofen did not modulate Aβ levels as
would be predicted if the compound has γ-secretase
modulating activity in vivo at the dose given acutely.
At a high dose, but within the therapeutic dosing range
(i.e., 800 mg IV-ibuprofen), there were no changes in Aβ
levels in human plasma. Even higher doses in nonhuman
primates, 100 mg/kg, failed to demonstrate Aβ42 reduc-
tion in CSF or plasma. In contrast, a second-generation
GSM, GSM-1, demonstrated potent changes in Aβ42 and
Aβ38 levels in CSF and plasma in monkeys indicative of
γ-secretase modulation. These latter findings showed that
γ-secretase complex can be modulated in primates in a
manner consistent with prototypic GSM activity first de-
fined in vitro and in rodents.
Epidemiological studies have consistently shown that
chronic usage of NSAIDs reduced the risk of AD and,
further, that the protective effects are linked with the
duration of NSAID use [17, 18, 42]. A recent study using
a Veterans Administration database reported that ibupro-
fen, one of the three most commonly used NSAIDs to-
gether with naproxen and indomethacin, had the strongest
protective effect against AD when used for more than 5
years [18]. However, there was no correlation between
NSAIDs that had GSM activity versus those that did not
[43]. In a 1-year treatment trial of mild to moderate AD
individuals, there was no benefit of 400 mg ibuprofen
given twice daily, but a sub-analysis of apoE4 individualssuggested slowing in cognitive decline [44]. Other treat-
ment trials with NSAIDs have either been negative or
demonstrated equivocal benefit [45–48].
Unresolved in all the observational studies are the
mechanisms by which NSAID use may lower the risk for
developing AD, if this happens [49]. A number of mech-
anisms have been proposed but none have been rigorously
tested [50]. In this study, we tested whether ibuprofen
may act as a GSM and reduce production of the patho-
genic Aβ42 peptides through this mechanism. In preclin-
ical studies, subacute treatment with 50 mg/kg ibuprofen
for 3 days significantly reduced Aβ42 but not Aβ40 levels
in the Tg2576 line of APP transgenic mice [16, 51].
Chronic treatment with ibuprofen decreased amyloid load
in the brain accompanied by reduction in all Aβ species,
and rescued memory deficits in the same APP transgenic
mouse line [16, 24, 26, 27], but the mechanisms for these
effects were not established. Furthermore, we are not
aware of a study in rodents that examined the changes in
Aβ peptides after acute treatment with ibuprofen to dem-
onstrate GSM activity, nor has the GSM activity of ibu-
profen been examined directly in primates. Results from
this study showed that, contrary to expectations, a single
high dose of ibuprofen did not reduce Aβ42 levels in mon-
keys or humans (Figs. 2 and 4). The maximum average
concentrations of total ibuprofen detected from plasma in
monkeys and human subjects were 1060.33 μM and
441.63 μM, respectively (Table 2). Although the assay
used in this study may be less quantitative than other
Fig. 5 Ibuprofen concentrations in human and monkey samples after
dosing. Ibuprofen concentrations were evaluated by ELISAs. a Plasma
samples from seven human subjects who received 800 mg of IV-ibuprofen
were analyzed. b Plasma and c cerebrospinal fluid (CSF) samples
from five monkeys treated with 100 mg/kg ibuprofen were evaluated
Table 2 Pharmacokinetics of ibuprofen in humans (800 mg)
and monkeys (100 mg/kg) after acute treatment
Human (n = 7) Monkey (n = 5)
Plasma CSF Plasma
Cmax total (μM)
a 441.63 ± 113.84 12.24 ± 8.18 1060.33 ± 565.25
AUC0–8h (μM*h) 831.44 ± 155.92 36.36 ± 11.75 3744.8 ± 924.16
CSF:plasma ratio 0.01 ± 0.004
aTotal concentration (bound and unbound). AUC0–8h area under the curve from
0 to 8 h, Cmax maximum average concentration, CSF cerebrospinal fluid
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spectrometry, the drug levels were within the range of
published reports [37]. Further, we did not measure free
versus bound concentration of the drug. However,because ibuprofen is about 99 % bound to plasma pro-
teins in humans [38], the estimated unbound concen-
tration of ibuprofen was ~4.4 μM. In mice treated with
50 mg/kg ibuprofen daily for 3 days and reported to
demonstrate GSM activity, the average plasma drug
concentration was 43 μM, 2 h after the last dose [51].
Because the unbound fraction of ibuprofen in rodents
has been reported to be ~5.5 % [52], the estimated
unbound ibuprofen concentration in that study would
be ~2.37 μM, a level that is comparable to what we
detected in humans. Consequently, the lack of effect
of ibuprofen in humans and monkeys cannot be easily
attributable to insufficient drug exposure, at least if
treatment for 3 days in mice is comparable to the single
acute treatment given in the present study. Another po-
tential explanation for the negative results is that, because
of lower efficacy, ibuprofen may require more sustained
treatment, as was done in the APP transgenic mouse line.
However, in view of the robust effects of GSM-1 in mon-
keys, this reasoning is perhaps less convincing. Therefore,
our results suggested that if subchronic to chronic treat-
ment of ibuprofen were effective in decreasing brain Aβ
levels in primates, it may not be due to direct γ-secretase
modulation, but possibly acting in combination with
other mechanisms, such as lowering pro-inflammatory
cytokines to decrease APP expression and Aβ accumu-
lation, increasing anti-inflammatory cytokines to facilitate
Aβ clearance, or anti-aggregation properties to reduce Aβ
fibril formation [50]. Interestingly, in the 5XFAD mice
with aggressive early amyloid pathology, 3 months of
treatment with ibuprofen resulted in an increase rather
than decrease in soluble Aβ levels and worsening of be-
havioral performance even in the presence of demon-
strated reduction in inflammatory responses. This study
in rodents called into question the beneficial effects of
anti-inflammatory treatments targeting the cyclooxygen-
ase pathway [53]. Taken together, the effects of ibuprofen
are complicated. If indeed they are beneficial in preventing
AD in humans, the mechanism of risk reduction may
occur through multiple pathways that have thus far not
been adequately tested in preclinical or clinical settings.
In stark contrast to ibuprofen, the second-generation
GSM-1 significantly decreased Aβ42 ratios in CSF and
plasma in monkeys. GSM-1 is a NSAID-derived carboxylic
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modulating compound structure to reduce lipophilicity
[19–21, 30]. The drug efficacy in transgenic mice was
first reported by Page and colleagues where a single dose
of GSM-1 given at even 3 mg/kg lowered brain Aβ42 by
25 % and, at 30 mg/kg, brain Aβ42 was reduced by 70 %
in APP transgenic mice. As would be expected, Aβ38
levels were concomitantly increased [28]. Consistent with
these rodent studies, we observed a 40 % reduction in ra-
tio of Aβ42/Aβ40 in plasma 4 h after dosing, whereas CSF
ratio of Aβ42 to total Aβ was decreased by 35 % 12 h after
treatment in monkeys (Fig. 2d,f ). At the same time,
changes in Aβ38 levels appeared more rapidly and were
more sustained (Fig. 2e). While the reciprocal Aβ42
and Aβ38 changes are one of the “signatures” of NSAID-
based GSMs, it is unclear whether these alterations are
mechanistically linked or occur independently. The un-
coupling of the two events had been reported in the
setting of presenilin 1 (PS1) or PS2 mutations [28, 54].
In addition, a recent study reported that a novel GSM
decreased both Aβ42 and Aβ38 levels while increasing
Aβ37 and Aβ39 peptides [55]. These results suggested
this coupling is not necessarily obligatory.
As expected, the second generation GSM-1 is much more
potent than ibuprofen in vitro with an ED50 of GSM-1 of
approximately 200 nM, compared to 250–500 μM for ibu-
profen (Fig. 1). Although not reported for GSM-1, a GSM
with similar structure and comparable in vitro and in vivo
GSM activity, GSM-10 h, demonstrated excellent brain
penetration in an APP transgenic mouse line (TASTPM)
[56]. In contrast, as estimated from the CSF to plasma
ratio, ibuprofen brain penetration was about 1 % in
monkeys (Table 2), a value consistent with other NSAIDs
[39, 40, 51]. Furthermore, NSAIDs such as fenofibrate and
flurbiprofen have been reported to bind to APP, presum-
ably one mechanism of action underlying the NSAID-
based GSMs [57]. On the other hand, GSM-1, like other
second-generation compounds, binds directly to the PS1
N-terminal fragment and through this interaction is be-
lieved to alter γ-secretase processing in an allosteric man-
ner [58–61]. Whether these differences in binding sites
confer different efficacy or mode of action has not been
established.
Conclusions
This study showed that a single high dose of ibuprofen
did not result in γ-secretase modulating activity in non-
human primates and humans. It is unclear whether mul-
tiple dosing would achieve the desired Aβ42 reduction
as this was not addressed in our study. However, a more
potent second-generation compound, GSM-1, selectively
decreased plasma and CSF Aβ42 levels in nonhuman pri-
mates in a manner consistent with the GSM class of drugs.
This study also reaffirms the utility of using a nonhumanprimate model to examine AD-targeted therapeutics in a
more physiologically relevant system.
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